Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aldurazyme Should Be Indicated For Symptomatic MPS I, Cmte. Says

Executive Summary

BioMarin/Genzyme's Aldurazyme should be indicated for symptomatic treatment of mucopolysaccharidosis I, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Jan. 15

You may also be interested in...



Genzyme Aldurazyme Patient Registry Will Evaluate AEs, Antibody Formation

BioMarin/Genzyme will develop an Aldurazyme patient registry to evaluate the long-term safety and activity of the product

Genzyme Aldurazyme Patient Registry Will Evaluate AEs, Antibody Formation

BioMarin/Genzyme will develop an Aldurazyme patient registry to evaluate the long-term safety and activity of the product

Aldurazyme complete response

Biomarin's Aldurazyme (laronidase) receives a complete response letter Jan. 28. FDA asked for more information on "postmarketing commitments, final product labeling, and completion of the manufacturing inspections process," Biomarin said. FDA completed its pre-approval inspections, and no further inspections are scheduled. The company expects Aldurazyme's postmarketing commitments to follow the Endocrinologic & Metabolic Drugs Advisory Committee recommendations of antibody formation monitoring. The committee unanimously recommended FDA approve Aldurazyme as treatment for mucopolysaccharidosis I (1"The Pink Sheet" Jan. 20, p. 18)...

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel